These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant. Ruggeri A; Sun Y; Labopin M; Bacigalupo A; Lorentino F; Arcese W; Santarone S; Gülbas Z; Blaise D; Messina G; Ghavamzadeh A; Malard F; Bruno B; Diez-Martin JL; Koc Y; Ciceri F; Mohty M; Nagler A Haematologica; 2017 Feb; 102(2):401-410. PubMed ID: 27758821 [TBL] [Abstract][Full Text] [Related]
10. Graft versus leukemia for "cell cure" of long-passage AKR leukemia after chemoradiotherapy. Saltzstein EC; Glasspiegel JS; Rimm AA; Giller RH; Bortin MM Cancer Res; 1972 Aug; 32(8):1658-62. PubMed ID: 4402951 [No Abstract] [Full Text] [Related]
11. [Immunosuppressive problems in organ transplantation]. Iwainsky H Z Erkr Atmungsorgane Folia Bronchol; 1970; 131(3):285-9. PubMed ID: 4395128 [No Abstract] [Full Text] [Related]
12. Time pattern of the antileukemic effect of graft-versus-host reaction in mice. Boranić M; Tonković I Cancer Res; 1971 Aug; 31(8):1140-7. PubMed ID: 4398523 [No Abstract] [Full Text] [Related]
13. Malononitrilamides inhibit the development of various murine graft-vs-host diseases. Schorlemmer HU; Kurrle R; Bartlett RR Transplant Proc; 1996 Dec; 28(6):3043-7. PubMed ID: 8962181 [No Abstract] [Full Text] [Related]
14. Rescue of rhesus monkeys from acute lethal graft-versus-host disease using cyclophosphamide and frozen autologous bone marrow. Merritt CB; Darrow CC; Vaal L; Herzig GP; Rogentine GN Transplantation; 1973 Jan; 15(1):154-9. PubMed ID: 4145721 [No Abstract] [Full Text] [Related]
15. Clinical and pathologic characteristics of graft-versus-host disease produced in cyclophosphamide-treated adult mice. Sandberg JS; Owens AH; Santos GW J Natl Cancer Inst; 1971 Jan; 46(1):151-60. PubMed ID: 4395991 [No Abstract] [Full Text] [Related]
16. Immunosuppressive power and limitations of FK 506 for prevention and treatment of graft-vs-host disease after small bowel transplantation. Platz KP; Mueller AR; Langrehr JM; Neuhaus P; Schraut WH Transplant Proc; 1996 Oct; 28(5):2523-4. PubMed ID: 8907933 [No Abstract] [Full Text] [Related]
17. Modification of graft-versus-host disease by neuraminidase treatment of donor cells. Decreased tolerogenicity of neuraminidase-treated cells. Im HM; Simmons RL Transplantation; 1971 Dec; 12(6):472-8. PubMed ID: 4399183 [No Abstract] [Full Text] [Related]
18. Enhancement of the immunosuppressive effect of graft-versus-host disease by partial-body irradiation. Lehnert S; Rybka WB Transplantation; 1985 Aug; 40(2):222-3. PubMed ID: 4040672 [No Abstract] [Full Text] [Related]
19. Rapamycin suppression of host-versus-graft and graft-versus-host disease in MHC-mismatched rats. Fabian MA; Denning SM; Bollinger RR Transplant Proc; 1992 Jun; 24(3):1174. PubMed ID: 1604575 [No Abstract] [Full Text] [Related]
20. The novel IMPDH inhibitor VX-497 prolongs skin graft survival and improves graft versus host disease in mice. Decker CJ; Heiser AD; Chaturvedi PR; Faust TJ; Ku G; Moseley S; Nimmesgern E Drugs Exp Clin Res; 2001; 27(3):89-95. PubMed ID: 11447770 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]